跳至主要内容
临床试验/EUCTR2022-002531-56-BE
EUCTR2022-002531-56-BE招募中1 期

ONGITUDINAL FOLLOW-UP OF SARS-COV-2 (COVID-19) IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO)A non-commercial multicenter academic prospective cohort study during 2023-2026 - COVICO

Sciensano0 个研究点目标入组 360 人开始时间: 2022年11月22日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
Sciensano
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Having participated in the previously organized PICOV-VAC, REDU-VAC, Lung-VAC or Nephro-VAC cohorts
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 200
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 160

排除标准

  • -Having a previous diagnosis of dementia and/or having a mini-mental state examination (MMSE) score < 18/30.
  • -Having veins which are not accessible for simple peripheral blood puncture.

研究者

发起方
Sciensano

相似试验